time get board pressur pascal
turn ew engin
ew thesi updat ew print shouldnt overtli
surpris investor tavr miss much
expect perhap increment ew
slash tavr cardioband estim
seem achiev analyst day come
like posit updat pipelin
decis ew share come
one view risk upsid bullish
mitral program bull qoq tavr share
stabil commentari strong provid
comfort ew held price steadi lap
present opportun longer term holder
believ ew best shot goal mitral
decid go ahead clasp us
worst behind us risk off-set
entri us shape
acceler growth year time get board
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
total sale maintain mm rang underli growth
fx full year
transcath heart valv therapi lower underli growth
mm prior underli growth rang
surgic heart valv therapi maintain mm underli sale growth
critic rais exceed underli growth mm underli
sale growth
gross margin maintain sale exclud special item
sg maintain sale
 maintain sale exclud special item
tax rate maintain le
free maintain high end mm
consign inventori convers complet end rais estim impact mm
mm vs prior mm mm
estimate global tavr procedur grow mid-teen
us tavr procedur grew mid-teen compar prior year
growth higher newer smaller center
ew ou procedur grew ldd market estim grow mid-teen
ww ew sale grew lower rate due modest y/i share declin ou lower royalti rev global asp stabl
estim eu tavr procedur grew mid teen howev ew experienc share loss share stabil quarter
japan new center continu qualifi fastest grow region quarter
ultra remain track receiv ce mark control roll-out strategi
target commerci intro centera eu w/ new deliveri system minim impact yr
mitral cardioband quarter due on-going suppli constraint expect trend continu
expect suppli constraint improv
pascal still expect eu launch
mid next year pascal data
minim impact result
continu expect data trial present march also lr data
formul draft revis ncd
ew assum chang current ncd unlik affect current tavr landscap
ncd final june
tax benefit employe stock comp exclud tax rate
fx ep quarter
top-line sale consign impact impact quarter convers complet ye
sg would lower consign exclud
quarter mm
capital-expenditure
total debt end
equival end
retir matur bond reduc amount
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin octob
analyst william tong alina levchuk vijay kumar primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
